Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Market Cap & Net Worth: Enzon Pharmaceuticals Inc (ENZN)
Enzon Pharmaceuticals Inc (OTCQX:ENZN) has a market capitalization of $7.42 Million ($7.42 Million) as of March 19, 2026. Listed on the OTCQX stock exchange, this USA-based company holds position #32991 globally and #10794 in its home market, demonstrating a -16.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enzon Pharmaceuticals Inc's stock price $0.10 by its total outstanding shares 74214603 (74.21 Million).
Enzon Pharmaceuticals Inc Market Cap History: 2015 to 2025
Enzon Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $15.64 Million to $7.42 Million (-6.45% CAGR).
Enzon Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enzon Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
228.35x
Enzon Pharmaceuticals Inc's market cap is 228.35 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.63x
Enzon Pharmaceuticals Inc's market cap is 7.63 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $15.64 Million | $17.46 Million | $21.64 Million | 0.90x | 0.72x |
| 2016 | $12.39 Million | $8.38 Million | -$1.13 Million | 1.48x | N/A |
| 2017 | $15.27 Million | $8.38 Million | $5.45 Million | 1.82x | 2.81x |
| 2018 | $14.25 Million | $6.92 Million | $5.85 Million | 2.06x | 2.44x |
| 2019 | $15.29 Million | $207.00K | -$979.00K | 73.86x | N/A |
| 2020 | $18.55 Million | $52.00K | -$1.31 Million | 356.80x | N/A |
| 2021 | $25.23 Million | $701.00K | -$469.00K | 36.00x | N/A |
| 2022 | $18.55 Million | $26.00K | -$186.00K | 713.60x | N/A |
| 2024 | $5.94 Million | $26.00K | $778.00K | 228.35x | 7.63x |
Competitor Companies of ENZN by Market Capitalization
Companies near Enzon Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Enzon Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Enzon Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Enzon Pharmaceuticals Inc's market cap moved from $15.64 Million to $ 7.42 Million, with a yearly change of -6.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.42 Million | +25.00% |
| 2024 | $5.94 Million | -11.11% |
| 2023 | $6.68 Million | -64.00% |
| 2022 | $18.55 Million | -26.47% |
| 2021 | $25.23 Million | +36.00% |
| 2020 | $18.55 Million | +21.36% |
| 2019 | $15.29 Million | +7.29% |
| 2018 | $14.25 Million | -6.71% |
| 2017 | $15.27 Million | +23.31% |
| 2016 | $12.39 Million | -20.79% |
| 2015 | $15.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Enzon Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.42 Million USD |
| MoneyControl | $7.42 Million USD |
| MarketWatch | $7.42 Million USD |
| marketcap.company | $7.42 Million USD |
| Reuters | $7.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.